Clinical trials: Antiviral Agents
Malignancy, Hepatitis B
Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine
Patients with chronic hepatitis B who are undergoing anticancer chemotherapy are at risk of HBV reactivation and hepatitis flare.
- Trial name
- NCT01580202
- Testing
- Entecavir, Lamivudine
- Where
- 5 sites in South Korea
- Volunteers
- 180 people
- Sponsor
- Seoul National University Hospital
Chronic Hepatitis C Virus Infection
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
The main objective of this study is to assess whether a recently-developed bioassay for the protein FGL2 can be used to predict the progression and/or response to treatment of Hepatitis C Virus disease in patients with chronic…
- Trial name
- NCT00606528
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Hepatitis C
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C
- Trial name
- NCT03402165
- Testing
- Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
- Where
- Egypt
- Volunteers
- 1,200 people
- Sponsor
- Sherief Abd-Elsalam
COVID-19 Acute Respiratory Distress Syndrome, Hypoxemia
Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia
This is an investigator initiated, single-center, open-label, Phase IIb clinical trial with 40 patients (for a total of 80 patients) to assess efficacy of Low molecular weight heparin using soft mist inhaler in the treatment of…
- Trial name
- NCT04990830
- Testing
- Inhaled Low molecular weight heparin, Standard Treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Istanbul University
SARS-CoV-2
ACE2 Chewing Gum on SARS-CoV-2 Viral Load (COVID 19)
A randomized double-blind, placebo controlled clinical trial of the safety, tolerability, and antiviral activity of angiotensin-converting enzyme 2 (ACE2) chewing gum over a 3-day period in non-hospitalized subjects with Severe…
- Trial name
- NCT05433181
- Testing
- ACE2 Chewing Gum
- Where
- United States
- Sponsor
- University of Pennsylvania
HIV, Art Therapy
Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens
This is a prospective, multicenter, open-label, parallel-controlled study. The primary objective is to prospectively explore and compare the virological efficacy of Ainuovirine/Lamivudine/Tenofovir and…
- Conditions
- HIV, Art Therapy, TB - Tuberculosis
- Trial name
- ALT VS TLE (NCT07631897)
- Testing
- Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets
- Volunteers
- 60 people
- Sponsor
- Shanghai Public Health Clinical Center
Chronic Hepatitis C Infection
Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects
The study is designed to test the hypothesis that the addition of a protease inhibitor to dual NS5a-NS5B nucleoside prodrug analog will enhance antiviral efficacy and hence shorten the treatment duration to 3 weeks.
- Trial name
- NCT02470858
- Testing
- LDV/SOF+ASV, SOF+DCV+SMV, SOF+DCV+ASV
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Humanity and Health Research Centre
Liver Disease
Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
More than 1.5 millions individuals are infected with HCV in Italy. They are at risk to develop related morbidity and mortality from cirrhosis and hepatocellular carcinoma, unless the evolution of their disease is halted by…
- Trial name
- NCT01437969
- Testing
- genotyping and/or sequencing
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
HBeAg Positive Chronic Hepatitis B
Study on Antiviral Therapy for HBeAg-positive Chronic Hepatitis B Patients Aged 1-16 Years
The purpose of this study is to provide theoretical and real world evidence for the optimization of antiviral treatment by IFN combined with Nucleosides analog in HBeAg positive chronic hepatitis B patients aged 1-16 years，so…
- Trial name
- NCT04565262
- Testing
- NAs+IFN-α
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Beijing 302 Hospital
Chronic Hepatitis B
Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatitis B Patients
The World Health Organization (WHO) has set a target to eliminate viral hepatitis by 2030, aiming for a 90% diagnosis rate and an 80% treatment rate for chronic hepatitis B (CHB).
- Trial name
- Union-FAST (NCT07520123)
- Testing
- Agent Intelligence education
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lymphoma
SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002571
- Testing
- bleomycin sulfate, filgrastim, cyclophosphamide
- Where
- 85 sites in United States
- Volunteers
- 52 people
- Sponsor
- SWOG Cancer Research Network
Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)
Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19
This project investigates individual treatments using convalescent severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2) plasma in SARS-CoV-2 infected patients at risk for disease progression.
- Trial name
- NCT04389944
- Testing
- convalescent plasma application to SARS-CoV-2 infected patients
- Where
- Switzerland
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Hepatitis C
A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects
The primary purpose of this study is to assess the change in HCV RNA during dosing with BMS-650032 and during the follow-up period in subjects with chronic hepatitis C infection
- Trial name
- NCT00722358
- Testing
- BMS-650032
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to add PMPA Prodrug (a new anti-HIV drug) to an anti-HIV drug combination taken by patients who have taken anti-HIV drugs in the past.
- Trial name
- NCT00002415
- Testing
- Tenofovir disoproxil fumarate
- Where
- 24 sites in United States
- Volunteers
- 175 people
- Sponsor
- Gilead Sciences
Chronic Genotype 1a or 1b HCV Infection
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects…
- Trial name
- NCT01434498
- Testing
- GS-5885 tablet, GS-9451 tablet, tegobuvir capsule
- Where
- 50 sites in United States, Canada and 1 more
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
HIV Infection, Endothelial Dysfunction
RAltegravir Switch STudy: Effects on Endothelial Recovery
Treatment with HIV-infection with protease inhibitors is associated with high blood lipids and higher chance for cardiovascular complications.
- Trial name
- RASSTER (NCT01453933)
- Testing
- raltegravir
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- UMC Utrecht
Hepatocellular Carcinoma
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological…
- Trial name
- NCT06325826
- Testing
- General Evaluation Score (GES)
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Egyptian Liver Hospital
Hepatitis C, Chronic
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1…
- Trial name
- NCT01353248
- Testing
- GS-5885, Tegobuvir, GS-9451
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 141 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Virus
Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV), administered for 8 or 12 weeks of treatment in…
- Trial name
- NCT01726517
- Testing
- LDV/SOF, RBV
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C Infection
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of 12 weeks of treatment with ACH-0143102 and ribavirin in genotype 1b (GT1b), treatment-naive, hepatitis C virus (HCV) participants.
- Trial name
- NCT01700179
- Testing
- ACH-0143102, Ribavirin
- Volunteers
- 8 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.